2339-PUB: Effect of IDegLira on HbA1c and Weight: Data from the Association of British Clinical Diabetologists (ABCD) IDegLira Audit

Autor:	Alistair N. Lumb, Karen Adamson, Ian W. Gallen, Alex Bickerton, Sing Yee Sim, Sean Noronha, Robert Elford John Ryder
Rok vydání:	2019
Předmět:	medicine.medical_specialty business.industry Patient Empowerment Liraglutide Endocrinology Diabetes and Metabolism Type 2 diabetes Audit Primary care medicine.disease Clinical trial Clinical Practice Internal medicine Internal Medicine Medicine Once daily business medicine.drug
Zdroj:	Diabetes. 68
ISSN:	1939-327X 0012-1797
Popis:	Unique in the UK armoury of injectable agents for diabetes, the combination IdegLira offers the clinical advantages of degludec and liraglutide, with the convenience of a once daily injection. The ABCD IDegLira audit, commenced in April 2017, is a nationwide audit evaluating whether the favourable effects of IDegLira on HbA1c and weight previously shown in clinical trials translate into similar advantages when the agent is used in real clinical practice. Data to date has been obtained nationwide via two routes: a physician populated online audit tool and a cloud-based IT system (Eclipse), capable of integrating with existing primary care systems to facilitate audit, risk stratification and patient empowerment. The inclusion criteria were people with type 2 diabetes started on IDegLira, who had HbA1c and weight measured at baseline and 6 months into treatment. Baseline values were defined as the most recent values in the 6-month period prior to initiation of IDegLira. Endpoint data was accepted within a collection window of +/- 45 days. We identified thirty-five patients for HbA1c (15M, 20F, mean ± SD age 57.4 ± 8.2) and twenty-eight patients for weight (13M, 15F, mean ± SD age 75.0 ± 8.6). Baseline HbA1c and weight were compared with the 6-month values with 2-sided p-values using a paired T Test. Mean ± SD HbA1c fell by 1.43% ± 2.04, from 10.17% ± 1.93 to 8.73% ± 1.74 (p Disclosure S. Noronha: None. A.N. Lumb: Advisory Panel; Self; Dexcom, Inc., Novo Nordisk A/S. Consultant; Self; LifeScan, Inc. Speaker's Bureau; Self; Abbott, Novo Nordisk A/S. Other Relationship; Self; Abbott. A. Bickerton: Employee; Self; MyWay Digital Health. S. Sim: None. I.W. Gallen: None. K. Adamson: None. R.E. Ryder: Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Bioquest. Funding Association of British Clinical Diabetologists
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e6c913c7f58ea343ecb4f24b7a02a215 https://doi.org/10.2337/db19-2339-pub Zobrazit plný text záznamu